Rock Springs Capital Management LP raised its holdings in shares of Pharvaris N.V. (NASDAQ:PHVS – Free Report) by 3.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 645,533 shares of the company’s stock after buying an additional 22,131 shares during the period. Rock Springs Capital Management LP’s holdings in Pharvaris were worth $18,236,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Pharvaris in the fourth quarter worth $35,000. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares in the last quarter. Barclays PLC purchased a new stake in Pharvaris during the 4th quarter worth $77,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Pharvaris during the 4th quarter worth $86,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Pharvaris in the 4th quarter valued at $110,000.
Insider Transactions at Pharvaris
In other Pharvaris news, Director Elisabeth Bjork sold 10,000 shares of Pharvaris stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $29.32, for a total transaction of $293,200.00. Following the sale, the director directly owned 15,167 shares in the company, valued at $444,696.44. The trade was a 39.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Wim Souverijns sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $29.92, for a total value of $299,200.00. Following the completion of the transaction, the insider directly owned 45,111 shares in the company, valued at approximately $1,349,721.12. The trade was a 18.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 274,555 shares of company stock valued at $8,880,601 in the last three months.
Pharvaris Price Performance
Pharvaris (NASDAQ:PHVS – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. As a group, equities analysts expect that Pharvaris N.V. will post -2.97 earnings per share for the current year.
Analyst Upgrades and Downgrades
PHVS has been the topic of a number of recent research reports. Royal Bank Of Canada reduced their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a report on Tuesday, June 16th. Wall Street Zen lowered Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Wedbush boosted their price target on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $50.08.
Check Out Our Latest Report on Pharvaris
Pharvaris Profile
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Featured Articles
- Five stocks we like better than Pharvaris
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Want to see what other hedge funds are holding PHVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pharvaris N.V. (NASDAQ:PHVS – Free Report).
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
